Diabetic Cataract R&D Services
Diabetic cataract (DC) is one of the major causes of visual impairment in diabetic individuals. The complexity of its pathogenesis and the urgency of early intervention place high demands on research and development tools. Ace Therapeutics providies full-cycle R&D services to global pharmaceutical companies, medical device companies, and research institutions based on our experience in diabetes animal modeling and ophthalmic disease research. From pathogenesis to therapeutic validation, we accelerate the translation of safe and effective DC drugs and devices into the market.
Introduction to Diabetic Cataracts
Cataracts are the leading cause of blindness worldwide. The incidence of cataracts in individuals with diabetes is not only three to five times higher than in the healthy population, but it is also occurring at an increasingly younger age. individuals with type 1 diabetes develop cataracts an average of 20 years earlier than non-diabetic individuals. In addition, prolonged diabetes and poor metabolic control increase the risk of developing cataracts.
Fig. 1 Cataracts related to diabetes. (Mrugacz, M.; et al., 2023)
Diabetic Cataract R&D Services at Ace Therapeutics
Diabetic cataract research and development requires precise mechanism analysis tools and efficient translational platforms. Our team consists of diabetologists, ophthalmic pathologists, and pharmacovigilance evaluation team pairs, and is committed to providing professional preclinical services to our clients.
Diabetic Cataract Modeling Services
Our core service capabilities include:
We develop established diabetic models (STZ‑induced or genetic) with precise control over cataract onset and progression by modulating hyperglycemia duration and glucose levels.
- Cellular & mechanistic models
We utilize high‑glucose/AGE‑stimulated lens epithelial cells to enable in‑depth investigation of key pathological mechanisms, such as oxidative stress, osmotic imbalance, and protein misfolding, thereby supporting robust target validation and lead compound screening.
- Advanced 3D organoid & ex vivo models
Our lens organoid and ex vivo culture systems closely recapitulate the native 3D microenvironment, allowing specific assessment of drug effects on lens transparency, metabolism, and cellular function for higher translational relevance.
We help our clients to analyze the molecular mechanism of diabetic cataract and provide theoretical basis for drug development.
- Utilizing animal models to study lens osmotic swelling, oxidative stress, and apoptosis.
- Analyzing the roles of key signaling pathways through proteomics and transcriptomics.
- Exploring the regulatory relationship of the lncRNA-miRNA axis.
Screening for highly effective and safe antidiabetic cataract drugs and combination therapies.
- High-throughput screening platform to assess AR inhibitory activity of natural compounds and synthetic drugs.
- Developing multi-targeted intervention programs combining antioxidants, anti-inflammatory agents and calcium homeostasis modulators.
Discovery and development of quantifiable and reproducible biomarker systems to assist in the early diagnosis and efficacy assessment of diabetic cataract.
- Analyze oxidative stress markers and inflammatory factors in the lens and aqueous humor.
- Identify genes and epigenetic regulators associated with lens epithelial cell apoptosis.
- Validate the predictive value of the identified biomarkers in diabetic cataract using multiple approaches.
Promote the development of early screening and precision diagnostic techniques for diabetic cataracts.
- Develop a biomarker-based rapid detection method to enable dynamic monitoring of disease status.
- Develop an AI-assisted diagnostic system based on deep learning, integrating technologies such as OCTA.
- Develop a smartphone-based remote fundus screening tool.
Advantages of Our Diabetic Cataract R&D Services
- Personalized customized service: Flexible adjustment of service modules according to the project stage to match the client's R&D needs.
- Multidisciplinary cross platform: Integrating molecular biology, pharmacology and artificial intelligence to build a comprehensive solution from basic research to preclinical translation.
- Advanced experimental technologies: High-throughput screening technology supports drug target screening and mechanism of action research. Deep learning algorithms are utilized to process image data to enhance diagnostic efficiency and accuracy.
Ace Therapeutics is committed to supporting early intervention, drug development and clinical translation of diabetic cataract by integrating multidisciplinary expertise. Please contact us for specific details. We will tailor a solution for your needs.
Reference
- Mrugacz, M.; et al. Current approach to the pathogenesis of diabetic cataracts. International Journal of Molecular Sciences. 2023, 24(7): 6317.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
